Cannabis Approvals up 1000% year on year
FreshLeaf Analytics, a Southern Cannabis Holdings (SCH) division, has released Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis.
The study was conducted in Q3 2019 and includes insights into the pricing and availability of legal medicinal cannabis products in the Australian marketplace including:
Number of products in market jumps 40% in 6 months
Patient growth continues at break-neck speed, up 1000% year on year
Overall spend declines as doctors go for cheaper products
Issues around vehicle driving and government subsidies remain
The report has been welcomed by the sector, with key players commenting:
Dr Sanjay Nijhawan, Medical Director of Cannabis Access Clinics: “It is encouraging to see that more patients are getting access to medicine that may help their condition”.
Tim Drury, CEO of Southern Cannabis Holdings: “The market has hit a tipping point here in Australia, and other pharmaceutical-style cannabis markets are looking to Australia as a source of best-practice in product standards, patient monitoring, clinical services and research”.
The report was developed using patient data that was analyzed over a period of July - August 2019. A full copy of the report can be downloaded from the FreshLeaf Analytics website.
About FreshLeaf Analytics
FreshLeaf Analytics, a division of Southern Cannabis Holdings, is the leading supplier of data about the medicinal cannabis industry in Australia. We have access to medicinal cannabis product, pricing and clinical data sets from some of Australia’s leading healthcare companies and organizations including healthcare clinics, pharmacies, product suppliers and the TGA. The FreshLeaf Analytics team provides custom research, analysis and consulting services in the Medicinal Cannabis market in Australia. The FreshLeaf Analytics team can be contacted on +61 2 8203 8741 or email@example.com
For media enquiries: firstname.lastname@example.org or call Belen 040 204 3146 or Mandy 045 903 4092.